NEW YORK--(BUSINESS WIRE)--Feb. 8, 2006--Callisto Pharmaceuticals, Inc. (AMEX:KAL)(FWB:CA4), a developer of new drug treatments in the fight against cancer and other major health threats, today announced that it has appointed Dr. Moshe Talpaz, Professor of Medicine and Associate Director of the Cancer Center for Translational Research, and Associate Chief of Hematology and Oncology at the University of Michigan in Ann Arbor, to the position of Chairman of Callisto's Scientific Advisory Board. Dr. Talpaz, well known for his role in the clinical development of Gleevec(TM), is an internationally-recognized authority on leukemia and other blood cancers.
